紫杉醇联合米非司酮治疗子宫内膜癌疗效

Efficacy of estrazol combined with mifepristone for treating women with endometrial cancer

目的:探讨紫杉醇联合米非司酮对子宫内膜癌患者血清肿瘤标志物、MMP-9、VEGF水平的影响。方法:选取2015年1月—2019年12月在本院行子宫内膜癌治疗的96例患者,随机分为观察组与对照组。对照组采用紫杉醇治疗,观察组采用紫杉醇联合米非司酮治疗,比较两组治疗前后血清学指标和治疗效果。结果:治疗后观察组糖类抗原125(30.2±6.0 U/ml)、人附睾分泌蛋白4(28.4±13.1 pmol/L)、血管内皮生长因子(237.0±30.0 ng/L)、基质金属蛋白酶-9(281.1±85.5 ng/ml)以及各项炎症因子水平均低于对照组,治疗优良率(91.7%)高于对照组(75.0%)(均P<0.05)。结论:紫杉醇联合米非司酮治疗子宫内膜癌,能够显著降低患者血清肿瘤标志物、炎症因子水平,明显改善机体炎性应急反应,治疗效果更佳。

Objective:To investigate the effect of paclitaxel combined with mifepristone for treating patients with endometrial cancer on their serum tumor markers,matrix metalloproteinase-9(MMP-9),and vascular endothelial growth factor(VEGF)levels.Methods:96 patients with endometrial cancer were selected and were randomly divided into two groups from January 2015 to December 2019.The patients in the control group were treated by paclitaxel,and the patients in the study group were treated by paclitaxel combined with mifepristone.The levels of serum tumor markers,VEGF,MMP-9,and inflammatory factors of the patients were compared between the two groups and between before and after treatment.Results:After treatment,the levels of carbohydrate antigen 125(30.2±6.0 U/ml),human epididymal secreted protein 4(28.4±13.1 pmol/L),VEGF(237.0±30.0 ng/L),MMP-9(281.1±85.5 ng/ml),and the inflammatory factors of the patients in the study group were significant lower than those of the patients in the control group,and the excellent and good efficacy rate of curative effect(91.7%)of the patients in the study group was significant higher than that(75.0%)of the patients in the control group(all P<0.05).Conclusion:Paclitaxel combined with mifepristone for treating patients with endometrial cancer can significantly reduce the levels of serum tumor markers and inflammatory factors,and can significantly improve the inflammatory emergency response of their body,so which has better therapeutic effect.